Company Filing History:
Years Active: 2017
Title: Etsuko Takeiri: Innovator in Cancer Therapeutics
Introduction
Etsuko Takeiri is a notable inventor based in Shizuoka, Japan. He has made significant contributions to the field of cancer therapeutics through his innovative research and development of antibodies.
Latest Patents
Etsuko Takeiri holds a patent for a "Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient." This patent describes the successful production of anti-Epiregulin antibodies that demonstrate cross-species reactivity between cynomolgus monkeys and humans. The antibodies have been engineered to suppress chemical degradation, lower isoelectric points, increase thermal denaturation midpoint temperatures, and reduce aggregate amounts. These advancements enable the antibodies to inhibit the growth of cancer cells by exhibiting cytotoxic and neutralizing activities against human Epiregulin-expressing cancer cells. He has 1 patent to his name.
Career Highlights
Etsuko Takeiri is associated with Chugai Seiyaku Kabushiki Kaisha, a prominent company in the pharmaceutical industry. His work focuses on developing innovative therapeutic agents that target cancer, showcasing his commitment to advancing medical science.
Collaborations
Etsuko has collaborated with notable colleagues, including Hirotake Shiraiwa and Keiko Esaki, who contribute to the research and development efforts in their field.
Conclusion
Etsuko Takeiri's work in developing humanized anti-Epiregulin antibodies represents a significant advancement in cancer therapy. His innovative approach and dedication to research continue to impact the medical community positively.